”2016 was a successful year for Morphosys. We applied for market approval through our pharmaceutical partner Janssen for the first therapeutic antibody based on our technology. We expect to hear the decision on the approval of Guselkumab in the second half of 2017,” said Morphosys CEO Dr. Simon Moroney, commenting on the successful business year 2016. At the same time, according to Moroney, the biotech company now resident at the new attractive location in Steinkirchen “has achieved great progress with our own development candidates. In our pipeline we see many active compounds that have the potential to create new standards in the treatment of diseases – to the benefit of all our stakeholders, such as our partners, shareholders and above all patients. With a record number of 114 programs in research and development, our active compound portfolio is one of the broadest in the biopharmaceutical industry,” says Moroney.